Spyre Therapeutics Crescita futura

Criteri Future verificati 0/6

Si prevede che gli utili di Spyre Therapeutics diminuiranno a 17% all'anno, mentre si prevede che i suoi ricavi annuali cresceranno a 77.5% all'anno. Si prevede che l'EPS diminuirà di 10.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà -58.9% in 3 anni.

Informazioni chiave

-17.0%

Tasso di crescita degli utili

-10.92%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	25.3%
Tasso di crescita dei ricavi	77.5%
Rendimento futuro del capitale proprio	-58.91%
Copertura analitica	Good
Ultimo aggiornamento	20 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Mar 17

Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms

Summary Spyre Therapeutics, Inc. receives a Strong Buy rating, driven by positive phase 1 data and robust pipeline progress in IBD and rheumatic diseases. SPY001 demonstrated a half-life 4x greater than ENTYVIO, supporting quarterly or twice-yearly dosing for ulcerative colitis in the ongoing phase 2 SKYLINE trial. Accelerated recruitment in the phase 2 SKYWAY RA sub-study brings the anti-TL1A SPY072 data readout forward to Q3 2026, enhancing SYRE's near-term catalysts. SYRE's $757M cash position funds operations into H2 2028, supporting multiple clinical milestones and reducing near-term financing risk. Read the full article on Seeking Alpha

Articolo di analisi • Jul 15

Companies Like Spyre Therapeutics (NASDAQ:SYRE) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Mar 04

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Summary Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance sheet with $603.1 million in cash, providing a four-year runway at its current burn rate. SYRE's innovative combination therapy approach targets multiple inflammatory pathways, aiming for better efficacy and long-term disease control in ulcerative colitis. Upcoming clinical trials in 2025 and 2026 are critical for validating Spyre's therapies and determining its potential to shift the treatment paradigm. Read the full article on Seeking Alpha

Seeking Alpha • Dec 12

Spyre Therapeutics: Different Name, Same Tune

Summary Today, we take an in-depth look at Spyre Therapeutics, Inc., which has promising assets in early-stage development, including SPY001, SPY002, and SPY003. The company changed its name from Aeglea BioTherapeutics, Inc. late last year, and thanks to a recent capital raise, is extremely well funded. Analyst firms also appear optimistic around the company's developmental approach. An analysis of SYRE stock follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Oct 01

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Summary Spyre Therapeutics, Inc. interim data from the phase 1 study, using SPY001 in healthy volunteers, is expected by the end of 2024. SPY001 is an a4b7 inhibitor being developed to target IBD like Crohn's Disease and Ulcerative Colitis. The Crohn's Disease treatment market is projected to reach a value of $17.80 billion by 2033. The global Ulcerative Colitis market is expected to be $10.79 billion by 2030. Read the full article on Seeking Alpha

Seeking Alpha • Aug 18

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Aeglea BioTherapeutics (NASDAQ:AGLE) on Thursday said Europe's drug regulator had validated the company's marketing authorization application for enzyme pegzilarginase for the treatment of Arginase 1 deficiency. Shares of the micro-cap clinical-stage biotech soared 57.5% to $0.80 in postmarket trading. The application was submitted by AGLE's commercialization partner in Europe and Middle East, Immedica Pharma, AGLE said in a statement. Arginase 1 deficiency is a rare, inherited disorder in which there is complete or partial lack of the enzyme arginase in the liver and red blood cells. Aeglea (AGLE) earlier in Aug. reported a mixed set of Q2 results.

Seeking Alpha • Aug 04

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aeglea BioTherapeutics press release (NASDAQ:AGLE): Q2 GAAP EPS of -$0.27 (vs. -0.10 Y/Y) beats by $0.04. Revenue of $0.63M (-95.4% Y/Y) misses by $0.08M. Shares +5.07% PM.

Seeking Alpha • Dec 07

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Aeglea achieved primary endpoint in reducing arginine levels with its drug pegzilarginase for ARG1-D, which in turn reduced ammonia in the blood plasma, by an average of 80%. BLA filing of pegzilarginase for patients with ARG1-D is expected to occur in 1st half of 2022. Additional results from the phase 3 PEACE study, using pegzilarginase for patients with ARG1-D, are expected to be released at an upcoming medical meeting and in peer-reviewed medical journals. The company will also submit a regulatory application for pegzilarginase for ARG1-D, with its partner Immedica Pharma, to Europe and other Middle East countries in 2022.

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:SYRE - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2028	N/A	-334	-299	-285	9
12/31/2027	N/A	-297	-275	-247	12
12/31/2026	N/A	-260	-185	-164	12
3/31/2026	N/A	-149	-149	-186	N/A
12/31/2025	N/A	-127	-162	-169	N/A
9/30/2025	N/A	-118	-162	-162	N/A
6/30/2025	N/A	-162	-154	-154	N/A
3/31/2025	N/A	-159	-170	-170	N/A
12/31/2024	N/A	-150	-157	-157	N/A
9/30/2024	N/A	75	-151	-151	N/A
6/30/2024	N/A	88	-141	-156	N/A
3/31/2024	1	-103	-96	-111	N/A
12/31/2023	1	-95	-85	-100	N/A
9/30/2023	1	-294	-72	-87	N/A
6/30/2023	1	-273	-67	-67	N/A
3/31/2023	1	-78	-72	-72	N/A
12/31/2022	2	-84	-80	-80	N/A
9/30/2022	6	-85	-81	-81	N/A
6/30/2022	7	-88	-83	-83	N/A
3/31/2022	20	-72	-61	-60	N/A
12/31/2021	19	-66	-54	-54	N/A
9/30/2021	15	-68	-53	-52	N/A
6/30/2021	14	-66	-54	-52	N/A
3/31/2021	N/A	-80	-77	-74	N/A
12/31/2020	N/A	-81	-80	-76	N/A
9/30/2020	N/A	-80	-79	-75	N/A
6/30/2020	N/A	-83	-79	-75	N/A
3/31/2020	N/A	-80	-74	-72	N/A
12/31/2019	N/A	-78	N/A	-66	N/A
9/30/2019	N/A	-72	N/A	-57	N/A
6/30/2019	N/A	-62	N/A	-48	N/A
3/31/2019	2	-53	N/A	-41	N/A
12/31/2018	4	-44	N/A	-32	N/A
9/30/2018	5	-36	N/A	-31	N/A
6/30/2018	7	-32	N/A	-30	N/A
3/31/2018	6	-29	N/A	-27	N/A
12/31/2017	5	-27	N/A	-25	N/A
9/30/2017	5	-26	N/A	-23	N/A
6/30/2017	5	-25	N/A	-22	N/A
3/31/2017	5	-23	N/A	-20	N/A
12/31/2016	5	-22	N/A	-19	N/A
9/30/2016	5	-20	N/A	-15	N/A
6/30/2016	5	-17	N/A	-13	N/A
3/31/2016	7	-13	N/A	-12	N/A
12/31/2015	6	-12	N/A	-11	N/A
9/30/2015	5	-11	N/A	-13	N/A
6/30/2015	3	-11	N/A	-11	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che SYRE rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che SYRE rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che SYRE rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che SYRE non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che SYRE non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che SYRE non sarà più redditizia tra 3 anni.

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/05/24 00:50
Prezzo dell'azione a fine giornata	2026/05/22 00:00
Utili	2026/03/31
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Spyre Therapeutics, Inc. è coperta da 24 analisti. 12 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Colleen Kusy	Baird
Mayur Somaiya	BMO Capital Markets Equity Research
Julian Harrison	BTIG

Spyre Therapeutics Crescita futura

Criteri Future verificati 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 11% to US$67.43

Price target increased by 9.9% to US$64.36

Consensus revenue estimates increase by 48%

Price target increased by 20% to US$3.12

Consensus EPS estimates upgraded to US$0.61 loss

Price target decreased by 16% to US$2.27

Recent updates

Spyre Therapeutics Advances Six Mid-Stage Trials With Accelerated Data Readouts in 2026

New minor risk - Share price stability

Spyre Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $403 million.

Spyre Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Price target increased by 11% to US$67.43

Spyre Therapeutics, Inc., Annual General Meeting, May 27, 2026

Price target increased by 9.9% to US$64.36

Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms

Spyre Therapeutics, Inc. Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Third Quarter 2026

CEO & Director notifies of intention to sell stock

Spyre Therapeutics, Inc. Appoints Kate Tansey Chevlen as Chief Commercial Officer

New minor risk - Share price stability

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended Anti-IL-23 Antibody

CEO & Director notifies of intention to sell stock

New major risk - Shareholder dilution

New minor risk - Share price stability

Spyre Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $275.000003 million.

Spyre Therapeutics, Inc. Doses First Patient in Pioneering Phase 2 SKYway Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases

Chief Financial Officer recently sold US$300k worth of stock

Companies Like Spyre Therapeutics (NASDAQ:SYRE) Are In A Position To Invest In Growth

High number of new and inexperienced directors

Spyre Therapeutics, Inc. Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Spyre Therapeutics, Inc. Announces Poster Presentations at Digestive Disease Week 2025 Including Up to Eight Months of Follow-Up from an Ongoing Phase 1 Trial of SPY001

Spyre Therapeutics, Inc., Annual General Meeting, May 29, 2025

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of Spy003, Its Novel Half-Life Extended Il-23 Antibody

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Spyre Therapeutics: Different Name, Same Tune

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-Life Extended Anti-Tl1a Antibodies

Spyre Therapeutics, Inc. has completed a Follow-on Equity Offering.

Spyre Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Spyre Therapeutics, Inc. Announces Positive Interim Phase 1 Data from its First-In-Human Trial of SPY001

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

Spyre Therapeutics, Inc. Announces First Participants Dose in Phase 1 Trial of SPY001

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc., Annual General Meeting, May 13, 2024

Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding from a group of investors

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors

Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors

Spyre Therapeutics, Inc.(NasdaqCM:SYRE) dropped from NASDAQ Composite Index

Aeglea BioTherapeutics, Inc. Announces Appointment of Cameron Turtle as Principal Executive Officer

Aeglea Biotherapeutics, Inc. Regains Compliance with Nasdaq Listing Rule

Aeglea Biotherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Immedica Pharma signed an agreement to acquire global rights to pegzilarginase from Aeglea BioTherapeutics, Inc from Aeglea BioTherapeutics, Inc. (NasdaqCM:AGLE) for $115 million.

Aeglea Biotherapeutics Receives Approval from Nasdaq of the Transfer of the Listing of Its Common Stock from Nasdaq Global Market to the Nasdaq Capital Market

High number of new directors

Aeglea BioTherapeutics, Inc. announced that it expects to receive $210.000248 million in funding from a group of investors

New major risk - Share price stability

Aeglea Biotherapeutics, Inc. Announces the Termination of Jeffrey Goldberg as Chief Executive Officer

Aeglea BioTherapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 48%

Price target increased by 20% to US$3.12

Consensus EPS estimates upgraded to US$0.61 loss

Price target decreased by 16% to US$2.27

No longer forecast to breakeven

Aeglea BioTherapeutics Receives Written Notice from The Nasdaq Stock Market, LLC Regarding Minimum Bid Price Requirement for Continued Listing

Aeglea Biotherapeutics, Inc. Announces Resignation of Leslie Sloan as Chief Operating Officer

Aeglea Biotherapeutics, Inc. Announces Chief Executive Officer Changes

Aeglea BioTherapeutics, Inc. Appoints Linda Neuman as Chief Medical Officer

Price target increased to US$2.70

Consensus forecasts updated

Price target increased to US$2.70

Aeglea BioTherapeutics, Inc. Provides Clinical Progress and Regulatory Update for Homocystinuria Program

Insider recently bought US$50k worth of stock

Aeglea Biotherapeutics Announces Leadership Transition

Aeglea BioTherapeutics, Inc. Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Consensus forecasts updated